Unique ID issued by UMIN | UMIN000017968 |
---|---|
Receipt number | R000019516 |
Scientific Title | Retinal sensitivity in branch retinal vein occlusion after anti-VEGF therapy |
Date of disclosure of the study information | 2015/06/19 |
Last modified on | 2019/10/25 08:41:54 |
Retinal sensitivity in branch retinal vein occlusion after anti-VEGF therapy
Retinal sensitivity in BRVO after anti-VEGF therapy
Retinal sensitivity in branch retinal vein occlusion after anti-VEGF therapy
Retinal sensitivity in BRVO after anti-VEGF therapy
Japan |
Branch retinal vein occlusion
Ophthalmology |
Others
NO
To compare the changes in retinal sensitivity after ranibizumab therapy or combination theraphy of ranibizumab and laser photocoagulation in eyes with branch retinal vein occlusion.
Efficacy
Retinal sensitivity at 12 months
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine | Device,equipment | Maneuver |
Ranibizumab (Lucentis) intravitreal injection is performed at baseline. Measurement of the best corrected visual acuity and foveal thickness using optical coherence tomography are performed monthly. Ranibizumab (Lucentis) intravitreal injection is performed when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
Ranibizumab (Lucentis) intravitreal injection is performed at baseline. Measurement of the best corrected visual acuity and foveal thickness using optical coherence tomography are performed monthly. Ranibizumab (Lucentis) intravitreal injection is performed when visual acuity is less than 1.0 and foveal thickness is more than 250micrometers. Macular laser photocoagulation will be performed when visual acuity is less than 1.0 and foveal thickness is more than 250micrometers at month 3 and month 9.
18 | years-old | <= |
Not applicable |
Male and Female
Treatment naive patients of branch retinal vein occlusion with visual acuity of less than 1.0 and macular edema of more than 250 micrometers in foveal thickness.
Patients with history of treatment for branch retinal vein occlusion, possibility of pregnancy, allergy for ranibizumab, intraocular infection or severe inflammation will be excluded.
50
1st name | |
Middle name | |
Last name | Akira Ojima |
Fukushima Medical University
Department of Ophthalmology
1 Hikarigaoka, Fukushima, Japan
024-548-2111
ao@fmu.ac.jp
1st name | |
Middle name | |
Last name | Akira Ojima |
Fukushima Medical University
Department of Ophthalmology
1 Hikarigaoka, Fukushima, Japan
024-548-2111
ao@fmu.ac.jp
Department of Ophthalmology, Fukushima Medical University
Novartis Pharmaceuticals Japan
Profit organization
NO
2015 | Year | 06 | Month | 19 | Day |
Unpublished
Completed
2015 | Year | 06 | Month | 19 | Day |
2014 | Year | 12 | Month | 01 | Day |
2015 | Year | 06 | Month | 19 | Day |
2018 | Year | 03 | Month | 31 | Day |
2018 | Year | 03 | Month | 31 | Day |
2018 | Year | 11 | Month | 30 | Day |
2018 | Year | 12 | Month | 25 | Day |
2015 | Year | 06 | Month | 18 | Day |
2019 | Year | 10 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019516
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |